Document is current
Any future updates will be listed below
-
Authors
Meng, Hao
Liao, Zhiying
Ji, Yanting
Wang, Dong
Han, Yang
Huang, Chaolin
Hu, Xujuan
Chen, Jingyi
Zhang, Hengrui
Li, Zonghong https://orcid.org/0000-0002-5153-0007
Wang, Changliang https://orcid.org/0000-0001-9561-3499
Sun, Hui
Sun, Jiaqi
Chen, Lihua https://orcid.org/0000-0003-3369-1875
Yin, Jiaxiang
Zhao, Jincun https://orcid.org/0000-0003-2515-5589
Xu, Tao
Liu, Huisheng https://orcid.org/0000-0001-5371-7943
- License Information
-
More Information
Article History
Received: 5 January 2023
Revised: 4 March 2024
Accepted: 10 March 2024
First Online: 23 April 2024
Competing interests
: The authors declare no competing interests.
: All work involving human embryonic stem cell (hESC) line H1 (WiCell Research Institute) was approved and reviewed by the Institutional Review Board of Guangzhou National Laboratory. All work involving live SARS-CoV-2 was performed at the Biosafety Level 3 Laboratories of Guangzhou Customs District Technology Center (Bioland, Guangzhou, China) and approved by the ethics committee. Experiments involving animal models were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangzhou National Laboratory. All studies involving human participants were approved by Institutional Review Board (IRB) of Wuhan Jinyintan Hospital.
